Changes in Hong Kong stocks | Verishibo-B (09887) rose more than 26%, and Velisign® listing application included in priority review and commercialization process accelerated across the board

The Zhitong Finance App learned that Weilizhibo-B (09887) rose by more than 26%. As of press release, it had risen 26.8% to HK$63.3 million, with a turnover of HK$163 million.

According to the news, on July 10, Verishibo announced that the PD-L1/4-1BB bispecific antibody Virixine® (LBL-024) biological product marketing license application (BLA) for treating advanced extrapulmonary neuroendocrine cancer (EP-NEC) independently developed by the company was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for inclusion in the priority review and approval process.

According to the company, this milestone marks the official closure of the commercialization schedule for Velisign®, and the approval period for listing can clearly be expected. At the same time, Weilizhibo is actively promoting various commercialization preparations before listing to ensure that the product can be introduced to the market as soon as it is approved. Orient Securities previously stated that based on the clinical progress of LBL-024, it is expected that key data on its core indications will be announced at the WCLC and ESMO conferences in September this year to verify its potential value in the field of major diseases and pan-oncology, and is expected to usher in a critical window for BD to go overseas.